Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
      Google Scholar   
Citation:
Ann Oncol vol 33 (4) 384-94
Year:
2022
Type:
Manuscript
Funding:
AFT
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
11
Parents:
3604  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
AbbVie Inc.  
Grants:
 
Corr. Author:
 
Authors:
                                           
Networks:
 
Study
AFT-04
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
carboplatin, neoadjuvant chemotherapy, phase III, triple-negative breast cancer, veliparib